Vincristine sulfate
Marqibo, Oncovin, Vincasar, Vincrex (vincristine sulfate) is a small molecule pharmaceutical. Vincristine sulfate was first approved as Oncovin on 1982-01-01. It is used to treat hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, and rhabdomyosarcoma amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vincasar pfs | ANDA | 2020-09-30 |
| vincristine sulfate | ANDA | 2023-02-03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
898 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 45 | 75 | 36 | 19 | 8 | 163 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 30 | 48 | 18 | 2 | 1 | 80 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 19 | 27 | 10 | 1 | 2 | 52 | |
| Follicular lymphoma | D008224 | C82 | 13 | 12 | 8 | 1 | — | 26 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 6 | 13 | 4 | 1 | — | 20 | |
| Burkitt lymphoma | D002051 | C83.7 | 10 | 10 | — | 2 | — | 19 | |
| Neoplasms | D009369 | C80 | 9 | 4 | 1 | 1 | — | 14 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 5 | 4 | 1 | 1 | — | 9 | |
| Wilms tumor | D009396 | 2 | 3 | 2 | 1 | — | 7 | ||
| Enteropathy-associated t-cell lymphoma | D058527 | C86.2 | 1 | 3 | — | 1 | — | 4 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 22 | 99 | 51 | — | 9 | 170 | |
| Leukemia | D007938 | C95 | 9 | 39 | 30 | — | 5 | 77 | |
| Neuroblastoma | D009447 | EFO_0000621 | 12 | 19 | 13 | — | 3 | 47 | |
| Central nervous system neoplasms | D016543 | 6 | 18 | 13 | — | 5 | 41 | ||
| Sarcoma | D012509 | 5 | 17 | 10 | — | 2 | 34 | ||
| Hodgkin disease | D006689 | C81 | 4 | 12 | 14 | — | 1 | 29 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | 6 | 8 | 5 | — | — | 18 | |
| B-cell lymphoma | D016393 | 11 | 8 | 3 | — | — | 18 | ||
| Retinoblastoma | D012175 | 3 | 9 | 3 | — | 2 | 16 | ||
| Medulloblastoma | D008527 | 3 | 8 | 5 | — | — | 15 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biphenotypic leukemia acute | D015456 | C95.0 | 3 | 5 | — | — | — | 7 | |
| Myelodysplastic syndromes | D009190 | D46 | 4 | 2 | — | — | — | 5 | |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 4 | 3 | — | — | — | 5 | ||
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 2 | 3 | — | — | — | 5 | |
| Plasmablastic lymphoma | D000069293 | C83.3 | 4 | 2 | — | — | — | 4 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 2 | 3 | — | — | — | 4 | |
| Primary effusion lymphoma | D054685 | C83.8 | 3 | 3 | — | — | — | 3 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 2 | — | — | — | 3 |
| Myeloid leukemia chronic-phase | D015466 | — | 2 | — | — | — | 2 | ||
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | 2 | 1 | — | — | — | 2 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoid leukemia | D007945 | C91 | 2 | — | — | — | — | 2 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
| Pinealoma | D010871 | 1 | — | — | — | — | 1 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | — | — | — | — | 1 | |
| Deltaretrovirus infections | D006800 | EFO_1001303 | 1 | — | — | — | — | 1 | |
| Syndrome | D013577 | 1 | — | — | — | — | 1 | ||
| Composite lymphoma | D058617 | 1 | — | — | — | — | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Recurrence | D012008 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Ototoxicity | D000081015 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VINCRISTINE SULFATE |
| INN | vincristine |
| Description | Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine. |
| Classification | Small molecule |
| Drug class | vinca alkaloids |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 57-22-7 |
| RxCUI | 11202 |
| ChEMBL ID | CHEMBL501867 |
| ChEBI ID | 79401 |
| PubChem CID | 5978 |
| DrugBank | DBSALT000314 |
| UNII ID | 5J49Q6B70F (ChemIDplus, GSRS) |
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Marqibo - Spectrum Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 50,829 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vincasar pfs, Vincristine sulfate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,098 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more